Savara Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Molgramostim Nebulizer Solution Expanded Access Program Protocol

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

First Posted Date: 2024-08-09

Last Posted Date: 2024-10-03

Lead Sponsor: Savara Inc.

Registration Number: NCT06546098

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Phase 3

Not yet recruiting

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Interventions: Drug: Molgramostim

First Posted Date: 2024-05-29

Last Posted Date: 2024-05-29

Lead Sponsor: Savara Inc.

Target Recruit Count: 5

Registration Number: NCT06431776

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Phase 3

Active, not recruiting

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Interventions: Drug: Molgramostim
Drug: Placebo

First Posted Date: 2020-09-10

Last Posted Date: 2024-10-31

Lead Sponsor: Savara Inc.

Target Recruit Count: 160

Registration Number: NCT04544293

Locations: 🇺🇸
University Of Arkansas For Medical Services, Little Rock, Arkansas, United States
🇺🇸
UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

and more 51 locations

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Phase 2

Terminated

Conditions: Mycobacterium Infections, Nontuberculous
Cystic Fibrosis (CF)

Interventions: Drug: Molgramostim nebulizer solution
Device: PARI eFlow nebulizer system

First Posted Date: 2018-07-24

Last Posted Date: 2023-01-10

Lead Sponsor: Savara Inc.

Target Recruit Count: 14

Registration Number: NCT03597347

Locations: 🇺🇸
University of North Carolina at Chapel Hill - UNC Marisco Clinical Research Center, Chapel Hill, North Carolina, United States
🇺🇸
Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸
UT Southwestern Medical Center Dallas, Dallas, Texas, United States

and more 2 locations

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Phase 3

Terminated

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Interventions: Drug: Molgramostim

First Posted Date: 2018-03-29

Last Posted Date: 2024-07-03

Lead Sponsor: Savara Inc.

Target Recruit Count: 60

Registration Number: NCT03482752

Locations: 🇩🇰
Dept. Of Respiratory Diseases & Allergy, Århus, Denmark
🇫🇷
CHU Rennes Hospital Pontchaillou, Service de Pneumologie, Rennes, France
🇩🇪
Ruhrlandklinik Essen Westdeutsches Lungenzentrum am Universitätsklinikum Essen GmbH, Essen, Germany

and more 10 locations

Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection

Phase 2

Completed

Conditions: Mycobacterium Infections, Nontuberculous

Interventions: Drug: Inhaled molgramostim
Drug: Antimycobacterial regimen

First Posted Date: 2018-02-05

Last Posted Date: 2024-07-03

Lead Sponsor: Savara Inc.

Target Recruit Count: 32

Registration Number: NCT03421743

Locations: 🇦🇺
The Prince Charles Hospital, Chermside West, Queensland, Australia
🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺
Greenslopes Private Hospital, Greenslopes, Queensland, Australia

and more 2 locations

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis
MRSA

Interventions: Drug: Vancomycin inhalation powder
Drug: Placebo inhalation powder

First Posted Date: 2017-06-09

Last Posted Date: 2022-12-16

Lead Sponsor: Savara Inc.

Target Recruit Count: 188

Registration Number: NCT03181932

Locations: 🇺🇸
University Vermont Medical Center Vermont Lung Center, Colchester, Vermont, United States
🇺🇸
Chicago CF Care Specialists, Glenview, Illinois, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 68 locations

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Phase 2

Completed

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Interventions: Drug: Placebo
Drug: Molgramostim
Device: PARI eFlow nebulizer system

First Posted Date: 2016-03-08

Last Posted Date: 2023-04-12

Lead Sponsor: Savara Inc.

Target Recruit Count: 139

Registration Number: NCT02702180

Locations: 🇯🇵
Tohoku University Hospital, Sendai, Japan
🇺🇸
University of Florida, Gainesville, Florida, United States
🇮🇱
Rabin Medical Center, Petaẖ Tiqwa, Israel

and more 27 locations

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Phase 1

Completed

Conditions: Pulmonary Alveolar Proteinosis
Bronchiectasis
Cystic Fibrosis
Acute Respiratory Distress Syndrome

Interventions: Drug: Placebo
Drug: Molgramostim

First Posted Date: 2015-06-11

Last Posted Date: 2017-02-23

Lead Sponsor: Savara Inc.

Target Recruit Count: 42

Registration Number: NCT02468908

Locations: 🇬🇧
Celerion, Belfast, United Kingdom

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo inhalation powder
Drug: Vancomycin hydrochloride inhalation powder

First Posted Date: 2012-12-10

Last Posted Date: 2020-01-13

Lead Sponsor: Savara Inc.

Target Recruit Count: 87

Registration Number: NCT01746095

Locations: 🇺🇸
The Cystic Fibrosis Center of Chicago, Glenview, Illinois, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 35 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy